1. Home
  2. Shareholder and Investor Information
  3. Maruishi Pharmaceutical Co.,Ltd. and RaQualia Pharma Inc. Sign Letter of Intent for EP4 Antagonist (RQ-00000007)

Shareholder and Investor Information

MARUISHI PHARMACEUTICAL CO., LTD. AND RAQUALIA PHARMA INC.
SIGN LETTER OF INTENT FOR EP4 ANTAGONIST (RQ-00000007)

Aichi, Japan May 31, 2010 – Maruishi Pharmaceutical Co.,Ltd. (Maruishi) and RaQualia Pharma Inc. (RaQualia) today announced the signing of a Letter of Intent (“LOI”), granting exclusive rights to Maruishi for RaQualia’s EP4 Antagonist (RQ-00000007) for the treatment of post-operative and cancer-related pain.
Under the LOI, Maruishi will have Japan and East Asia rights to develop and commercialize the intravenous formulation of RQ-00000007. The two parties intend to complete a license agreement by the end of August 2010.
About RQ-00000007
RQ-00000007 is a potent and selective EP4 antagonist, which is expected to offer a new treatment option for the management of acute pain conditions. The intravenous formulation of RQ-00000007 will provide fast onset for the treatment of pain following major surgery. RQ-00000007 has the potential to be used in combination therapy with opioid analgesics. This may reduce opioid usage, decrease the risk of side effects, and significantly improve the quality of life for patients.
In addition to the acute pain indication, RaQualia is developing RQ-00000007 as a new, innovative therapy for the treatment of chronic pain, cancer, and autoimmune diseases.
About RaQualia
RaQualia Pharma Inc. engages in discovery, development and marketing of clinical and pre-clinical drug candidates. RaQualia’s vision is to bring people hope, health and happiness with new medicines.
About Maruishi
Maruishi Pharmaceutical Co.,Ltd. was founded in 1888 and is headquartered in Osaka, Japan. It develops and markets a variety of pharmaceutical products, particularly anesthetics and disinfectants. Information about Maruishi can be found on the world wide web at www.maruishi-pharm.co.jp.

Contact
・Maruishi Pharmaceutical Co.,Ltd.
Hideharu Tominaga / Kaoru Nagata
Phone: +81 6 6964 3150
Fax: +81 6 6965 6060
E-mail: strat_prod_planning@maruishi-pharm.co.jp

・RaQualia Pharma Inc.
Tim Kendall / Satoko Saito
Phone: +81 569 84 0700
Fax: +81 569 74 1381
E-mail: ask@raqualia.com

Page Top

Corporate Information
CEO Message
Company Overview
Vision, Management Principle and Culture
Quality Policy
Corporate Governance
Business Model
Origins of Our Corporate Name and Logo
Access
Press Release
Research & Development
Collaboration
Partnering in Research
What are Research Tools?
Research Tool Licensing
Product Information
Anidulafungin
Ziprasidone
Dalbavancin
Potassium-Competitive Acid Blocker
5-HT4 Partial Agonist
5-HT2B Antagonist
Motilin Receptor Agonist
Licensing Status
Shareholder and Investor Information
Vision, Management Principle and Culture
Corporate Governance
Outline of Securities Matters
IR Library
IR Calendar
Disclaimer
IR Related News
Understanding RaQualia Pharma! RaQualia FAQ
RaQualia's History
What does RaQualia Pharma do?
How Does RaQualia Earn Revenues?
What About Dividends?
What are RaQualia's strengths?
What Does the Future Hold for RaQualia Pharma?
Contributions to Society
Corporate Contributions
Contributions to the Community
Press Release
Topics